EGFR inhibitors (Gefitinib, PD153035 and AG1478), MAPK antagonist (PD98059) and PI3K inhibitor (LY294002) have shown their potential to inhibit survivin in breast, lung, pancreatic, colon and ovarian cancer cell lines [157–160]. Here, BIRC5 is linked to ovarian carcinoma.